• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Glooko Appoints Dr. Mark Clements as Chief Medical Officer

by Jasmine Pennic 05/21/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Glooko Appoints Dr. Mark Clements as Chief Medical Officer
Dr. Mark Clements, Chief Medical Officer at Glooko

Glooko, a provider of diabetes data management solutions, today announced the appointment of Mark Clements, MD, Ph.D., CPI, FAAP, as Chief Medical Officer. Dr. Clements joins the senior management team of Glooko having served on its medical advisory board since it was formed in 2015 to provide expertise to the organization in the areas of clinical studies and diabetes analytics. 

Dr. Clements comes to Glooko from the University of Missouri-Kansas City School of Medicine, where he is Associate Professor of Pediatrics. He is also a pediatric endocrinologist at Children’s Mercy Kansas City, where he serves as Director of Pediatric Endocrine/Diabetes Clinical Research and Medical Director for the Pediatric Clinical Research Unit. He will continue his work with the medical school and Children’s Mercy as he also takes on his new role with Glooko. Dr. Clements is also a clinical researcher of new diabetes treatments and technologies, having served as a principal investigator or co-investigator in more than 30 clinical studies and patient registries.

“We’re thrilled to have Mark join our executive leadership team at Glooko and bring the depth of experience he has in patient care as well as medical research and education,” said Russ Johannesson, CEO of Glooko. “This background combined with his expertise in turning data and analytics into practical insights for treating people with diabetes will be a significant advantage for us, especially as he provides leadership in the development of our future product portfolio and adds his perspective as clinician and investigator to our research efforts.”

“With diabetes technology today, the person with diabetes is able to accumulate enormous amounts of data about his or her diabetes and share it safely with healthcare professionals, and that ability is expanding rapidly,” said Dr. Clements. “That can provide a huge advantage in helping patients be more effective in managing their diabetes, but only if we provide tools that can help them see their data in the form of practical insights that they and their clinicians can use to effectively guide diabetes management. As the clear leader and a trusted partner in diabetes data management, Glooko is in a unique position to forge the path toward keeping data private and secure while making it usable and practical for patients and their providers, and I’m excited to be joining the organization in leading that effort.” 

Consistent with his research and leadership experience as well as his desire to find effective treatments for children with diabetes, Dr. Clements has also served as Pediatric Chair of the T1D Exchange Clinic Registry of the T1D Exchange, a nonprofit research and collaboration organization dedicated to accelerating novel therapies to improve the care of people living with Type 1 diabetes. 

Dr. Clements has published extensively in peer-reviewed medical journals and is sought after as a speaker, particularly on the topic of diabetes analytics and insights.

He earned his medical degree and a Ph.D. in developmental neuroscience from Washington University Medical School in St. Louis, and he completed a residency in pediatrics and a fellowship in pediatric endocrinology at the University of Missouri-Kansas City School of Medicine and Children’s Mercy Hospital.

Dr. Clements is board certified in pediatric endocrinology by the American Board of Pediatrics and is a fellow of the American Academy of Pediatrics (FAAP). He is also recognized as a certified principal investigator (CPI) by the Association of Clinical Research Professionals.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Advisory Board, clinical research, data management, diabetes, Diabetes Management, Glooko, MD, Patient Care, PhD, type 1 diabetes, WASHINGTON

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |